Similar articles

• Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer.

  Schneider PM, Metzger R, Schaefer H, Baumgarten F, Vallbohmer D, Brabender J, Wolfgarten E, Bollschweiler E, Baldus SE, Dienes HP, Hoelscher AH. Schneider PM, et al. Ann Surg. 2008 Dec;248(6):902-8. doi: 10.1097/SLA.0b013e31818f3afb. Ann Surg. 2008. PMID: 19092334
• Multi-modality treatment in oesophageal cancer: a curse for radiotherapy progress.

  Tait DM. Tait DM. Radiother Oncol. 2004 Nov;73(2):115-7. doi: 10.1016/j.radonc.2004.08.010. Radiother Oncol. 2004. PMID: 15542157 No abstract available.
• Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma?

  Elsaleh H, Farrell JJ, Crane CH. Elsaleh H, et al. J Gastroenterol Hepatol. 2009 May;24(5):708-10. doi: 10.1111/j.1440-1746.2009.05838.x. J Gastroenterol Hepatol. 2009. PMID: 19646012 No abstract available.
• [Neoadjuvant chemoradiotherapy in patients with surgically treated T4 esophageal squamous cell carcinnoma].

  Shiozaki H, Yano M. Shiozaki H, et al. Nihon Geka Gakkai Zasshi. 2002 Mar;103(3):284-9. Nihon Geka Gakkai Zasshi. 2002. PMID: 11968758 Review. Japanese.
• Pre-operative chemo-radiotherapy improves 3-year survival in people with resectable oesophageal cancer.

  Naughton P, Walsh TN. Naughton P, et al. Cancer Treat Rev. 2004 Feb;30(1):141-4. doi: 10.1016/j.ctrv.2003.11.009. Cancer Treat Rev. 2004. PMID: 14766133 Review. No abstract available.